Pharmacokinetics and Anti-Diabetic Studies of Gliclazide Nanosuspension.
Box–Behnken design
antisolvent precipitation
diabetes formulation
nanosuspension
quality by design
solubility
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
14 Sep 2022
14 Sep 2022
Historique:
received:
03
08
2022
revised:
10
09
2022
accepted:
12
09
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
24
9
2022
Statut:
epublish
Résumé
Gliclazide (GCZ), an antidiabetic medication, has poor solubility and limited oral bioavailability due to substantial first-pass metabolism. Thus, the purpose of the current study was to optimize and formulate a GCZ nanosuspension (NS) employing the antisolvent precipitation technique. A three-factor, three-level Box-Behnken design (BBD) was used to examine the impact of the primary formulation factors (drug concentration, stabilizer, and surfactant %) on particle size. The optimized NS contains 29.6 mg/mL drug, 0.739% lecithin, and 0.216% sodium dodecyl sulfate (SDS). Under scanning microscopy, the topography of NS revealed spherical particles. Furthermore, NS had a much better saturation solubility than the pure material, which resulted in a rapid dissolving rate, which was attributed to the amorphous structure and smaller particle size of the NS particles. Studies on intestinal permeability using the in vitro noneverted intestinal sac gut method (duodenum, jejunum, and ileum) and single-pass intestinal permeability (SPIP) techniques showed that the effective permeability was also increased by more than 3 fold. In the pharmacokinetic study, the C
Identifiants
pubmed: 36145695
pii: pharmaceutics14091947
doi: 10.3390/pharmaceutics14091947
pmc: PMC9500859
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Acta Pharm. 2008 Dec;58(4):379-92
pubmed: 19103573
Int J Pharm. 2009 Oct 1;380(1-2):216-22
pubmed: 19596059
Drug Dev Ind Pharm. 2007 Feb;33(2):101-11
pubmed: 17454041
J Pharm Sci. 2003 Apr;92(4):839-46
pubmed: 12661069
Drug Dev Ind Pharm. 2010 Aug;36(8):893-902
pubmed: 20196643
Int J Pharm. 2013 Jan 30;441(1-2):728-35
pubmed: 23089583
Nanomedicine. 2017 Feb;13(2):455-469
pubmed: 27558350
Drug Des Devel Ther. 2017 Aug 23;11:2443-2452
pubmed: 28860715
AAPS PharmSciTech. 2017 May;18(4):983-996
pubmed: 27506564
Drug Discov Today. 2022 Aug;27(8):2322-2332
pubmed: 35460893
Eur J Med Chem. 2006 May;41(5):605-10
pubmed: 16546303
AAPS PharmSciTech. 2019 Oct 28;20(8):326
pubmed: 31659558
Pharmaceutics. 2022 Apr 30;14(5):
pubmed: 35631564
Drugs. 1993 Jul;46(1):92-125
pubmed: 7691511
Pharmaceuticals (Basel). 2021 Aug 09;14(8):
pubmed: 34451883
Acta Pharm. 2011 Sep 1;61(3):323-34
pubmed: 21945911
J Microencapsul. 2017 Jun;34(4):416-429
pubmed: 28595495
Curr Drug Deliv. 2012 Sep;9(5):437-51
pubmed: 22920574
Eur J Pharm Sci. 2017 Jun 15;104:13-22
pubmed: 28315464
J Pharm Pharm Sci. 2009;12(3):250-65
pubmed: 20067702
Pharmacol Rep. 2015 Apr;67(2):339-44
pubmed: 25712660
J Control Release. 1998 Feb 12;51(2-3):185-92
pubmed: 9685916
AAPS PharmSciTech. 2019 Jan 7;20(2):45
pubmed: 30617566
Biopharm Drug Dispos. 2002 May;23(4):151-7
pubmed: 12015789
Nat Nanotechnol. 2021 Nov;16(11):1281-1291
pubmed: 34675410
Int J Nanomedicine. 2020 Feb 18;15:1129-1148
pubmed: 32110012
Biomater Res. 2020 Jan 15;24:3
pubmed: 31969986
Pharm Dev Technol. 2020 Oct;25(8):971-988
pubmed: 32403972
Pharmaceutics. 2022 Sep 03;14(9):
pubmed: 36145608
Pharm Res. 1995 Mar;12(3):413-20
pubmed: 7617530
Int J Pharm. 2015 Jan 15;478(1):131-137
pubmed: 25448575
Int J Nanomedicine. 2015 Oct 13;10:6425-34
pubmed: 26508852
Pharm Res. 1998 Jan;15(1):11-22
pubmed: 9487541
Eur J Pharm Biopharm. 2000 Nov;50(3):379-87
pubmed: 11072195
Int J Pharm. 2017 Apr 15;521(1-2):156-166
pubmed: 28223247
AAPS PharmSciTech. 2008;9(2):563-70
pubmed: 18459056
Adv Drug Deliv Rev. 2007 Jul 30;59(7):631-44
pubmed: 17601629
AAPS PharmSciTech. 2017 Nov;18(8):3151-3162
pubmed: 28534300
Chem Soc Rev. 2021 May 11;50(9):5746-5776
pubmed: 33972972
Analyst. 2013 Oct 21;138(20):6106-16
pubmed: 23964358
Eur J Pharm Sci. 2016 Dec 1;95:111-121
pubmed: 27181836
Pharmaceutics. 2022 Aug 27;14(9):
pubmed: 36145555
J Pharm Pharmacol. 2004 Jul;56(7):827-40
pubmed: 15233860
Int J Pharm. 2013 Nov 1;456(1):243-50
pubmed: 23928148
Eur J Pharm Biopharm. 2000 Jul;50(1):3-12
pubmed: 10840189
Langmuir. 2006 Oct 10;22(21):8951-9
pubmed: 17014140
Adv Pharm Bull. 2018 Aug;8(3):419-427
pubmed: 30276138
Curr Drug Metab. 2015;16(7):522-37
pubmed: 25523548
Biochem Pharmacol. 2006 Nov 30;72(11):1605-21
pubmed: 16889756
Saudi Pharm J. 2016 Jan;24(1):57-63
pubmed: 26903769
Eur J Pharm Sci. 2015 Oct 12;78:54-66
pubmed: 26143262
J Pharm Sci. 2014 Jul;103(7):2166-2176
pubmed: 24840928
Int J Mol Sci. 2021 Sep 30;22(19):
pubmed: 34638935
Int J Pharm. 2011 May 16;409(1-2):260-8
pubmed: 21371540
Int J Pharm. 2013 Aug 30;453(1):126-41
pubmed: 23333709
Int J Pharm. 2011 Mar 15;406(1-2):145-52
pubmed: 21185926
Int J Pharm. 2008 Nov 19;364(1):64-75
pubmed: 18721869
Phytomedicine. 2018 Feb 01;40:48-54
pubmed: 29496174
Pharmaceutics. 2022 Jul 11;14(7):
pubmed: 35890343
Int J Nanomedicine. 2008;3(3):295-309
pubmed: 18990939
Adv Drug Deliv Rev. 2001 Mar 23;47(1):3-19
pubmed: 11251242
Drug Deliv Transl Res. 2020 Oct;10(5):1476-1494
pubmed: 32519202
Pharmazie. 2002 Mar;57(3):191-3
pubmed: 11933849
Pharm Dev Technol. 2016 Mar;21(2):180-8
pubmed: 25427602
Int J Pharm. 2006 Apr 7;312(1-2):179-86
pubmed: 16469459